Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma

Shinichi Makita, Shigeo Fuji, Kuniko Takano, Takashi Tanaka, Yoshitaka Inoue, Reiko Ito, Ayumu Ito, Yoshiki Hayashi, Kinuko Tajima, Keiji Okinaka, Saiko Kurosawa, Sung Won Kim, Takuya Yamashita, Ryuji Tanosaki, Kensei Tobinai, Takahiro Fukuda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma. There are limited reports on allogeneic stem cell transplantation (allo-SCT) in patients with LBL. We retrospectively analyzed the clinical outcomes of 15 adult patients with LBL who received allo-SCT at our institution. The median age at allo-SCT was 29 years (range, 18-42). Disease status at the time of transplantation was complete remission (CR), partial remission (PR), and advanced disease in 4, 4, and 7 patients, respectively. The median follow-up duration of survivors was 25 months (range, 6-106). The probabilities of overall survival (OS) and progression-free survival (PFS) at 2 years after allo-SCT were 37% and 24%, respectively. The respective 2-year OS and PFS rates of the 8 patients with CR or PR at the time of transplantation were 57% and 45%, while those with advanced disease were 14% and 0%. In conclusion, the treatment outcomes of allo-SCT in patients with LBL were unsatisfactory. Although outcomes were promising in patients with CR or PR at the time of transplantation, they were dismal in patients with progressive disease. Further advances in chemotherapy, both induction and salvage therapies, are needed to improve the clinical outcomes of patients with LBL.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalJournal of clinical and experimental hematopathology : JCEH
Volume56
Issue number1
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplantation
Disease-Free Survival
Salvage Therapy
Induction Chemotherapy
Survival
Non-Hodgkin's Lymphoma
Survivors
Survival Rate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. / Makita, Shinichi; Fuji, Shigeo; Takano, Kuniko; Tanaka, Takashi; Inoue, Yoshitaka; Ito, Reiko; Ito, Ayumu; Hayashi, Yoshiki; Tajima, Kinuko; Okinaka, Keiji; Kurosawa, Saiko; Kim, Sung Won; Yamashita, Takuya; Tanosaki, Ryuji; Tobinai, Kensei; Fukuda, Takahiro.

In: Journal of clinical and experimental hematopathology : JCEH, Vol. 56, No. 1, 2016, p. 28-33.

Research output: Contribution to journalArticle

Makita, S, Fuji, S, Takano, K, Tanaka, T, Inoue, Y, Ito, R, Ito, A, Hayashi, Y, Tajima, K, Okinaka, K, Kurosawa, S, Kim, SW, Yamashita, T, Tanosaki, R, Tobinai, K & Fukuda, T 2016, 'Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma', Journal of clinical and experimental hematopathology : JCEH, vol. 56, no. 1, pp. 28-33. https://doi.org/10.3960/jslrt.56.28
Makita, Shinichi ; Fuji, Shigeo ; Takano, Kuniko ; Tanaka, Takashi ; Inoue, Yoshitaka ; Ito, Reiko ; Ito, Ayumu ; Hayashi, Yoshiki ; Tajima, Kinuko ; Okinaka, Keiji ; Kurosawa, Saiko ; Kim, Sung Won ; Yamashita, Takuya ; Tanosaki, Ryuji ; Tobinai, Kensei ; Fukuda, Takahiro. / Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. In: Journal of clinical and experimental hematopathology : JCEH. 2016 ; Vol. 56, No. 1. pp. 28-33.
@article{59886dd8a0444a529b6f7094361bd050,
title = "Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma",
abstract = "Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma. There are limited reports on allogeneic stem cell transplantation (allo-SCT) in patients with LBL. We retrospectively analyzed the clinical outcomes of 15 adult patients with LBL who received allo-SCT at our institution. The median age at allo-SCT was 29 years (range, 18-42). Disease status at the time of transplantation was complete remission (CR), partial remission (PR), and advanced disease in 4, 4, and 7 patients, respectively. The median follow-up duration of survivors was 25 months (range, 6-106). The probabilities of overall survival (OS) and progression-free survival (PFS) at 2 years after allo-SCT were 37{\%} and 24{\%}, respectively. The respective 2-year OS and PFS rates of the 8 patients with CR or PR at the time of transplantation were 57{\%} and 45{\%}, while those with advanced disease were 14{\%} and 0{\%}. In conclusion, the treatment outcomes of allo-SCT in patients with LBL were unsatisfactory. Although outcomes were promising in patients with CR or PR at the time of transplantation, they were dismal in patients with progressive disease. Further advances in chemotherapy, both induction and salvage therapies, are needed to improve the clinical outcomes of patients with LBL.",
author = "Shinichi Makita and Shigeo Fuji and Kuniko Takano and Takashi Tanaka and Yoshitaka Inoue and Reiko Ito and Ayumu Ito and Yoshiki Hayashi and Kinuko Tajima and Keiji Okinaka and Saiko Kurosawa and Kim, {Sung Won} and Takuya Yamashita and Ryuji Tanosaki and Kensei Tobinai and Takahiro Fukuda",
year = "2016",
doi = "10.3960/jslrt.56.28",
language = "English",
volume = "56",
pages = "28--33",
journal = "Journal of clinical and experimental hematopathology : JCEH",
issn = "1346-4280",
publisher = "Nihon Rinpa Monaikei Gakkai",
number = "1",

}

TY - JOUR

T1 - Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma

AU - Makita, Shinichi

AU - Fuji, Shigeo

AU - Takano, Kuniko

AU - Tanaka, Takashi

AU - Inoue, Yoshitaka

AU - Ito, Reiko

AU - Ito, Ayumu

AU - Hayashi, Yoshiki

AU - Tajima, Kinuko

AU - Okinaka, Keiji

AU - Kurosawa, Saiko

AU - Kim, Sung Won

AU - Yamashita, Takuya

AU - Tanosaki, Ryuji

AU - Tobinai, Kensei

AU - Fukuda, Takahiro

PY - 2016

Y1 - 2016

N2 - Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma. There are limited reports on allogeneic stem cell transplantation (allo-SCT) in patients with LBL. We retrospectively analyzed the clinical outcomes of 15 adult patients with LBL who received allo-SCT at our institution. The median age at allo-SCT was 29 years (range, 18-42). Disease status at the time of transplantation was complete remission (CR), partial remission (PR), and advanced disease in 4, 4, and 7 patients, respectively. The median follow-up duration of survivors was 25 months (range, 6-106). The probabilities of overall survival (OS) and progression-free survival (PFS) at 2 years after allo-SCT were 37% and 24%, respectively. The respective 2-year OS and PFS rates of the 8 patients with CR or PR at the time of transplantation were 57% and 45%, while those with advanced disease were 14% and 0%. In conclusion, the treatment outcomes of allo-SCT in patients with LBL were unsatisfactory. Although outcomes were promising in patients with CR or PR at the time of transplantation, they were dismal in patients with progressive disease. Further advances in chemotherapy, both induction and salvage therapies, are needed to improve the clinical outcomes of patients with LBL.

AB - Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma. There are limited reports on allogeneic stem cell transplantation (allo-SCT) in patients with LBL. We retrospectively analyzed the clinical outcomes of 15 adult patients with LBL who received allo-SCT at our institution. The median age at allo-SCT was 29 years (range, 18-42). Disease status at the time of transplantation was complete remission (CR), partial remission (PR), and advanced disease in 4, 4, and 7 patients, respectively. The median follow-up duration of survivors was 25 months (range, 6-106). The probabilities of overall survival (OS) and progression-free survival (PFS) at 2 years after allo-SCT were 37% and 24%, respectively. The respective 2-year OS and PFS rates of the 8 patients with CR or PR at the time of transplantation were 57% and 45%, while those with advanced disease were 14% and 0%. In conclusion, the treatment outcomes of allo-SCT in patients with LBL were unsatisfactory. Although outcomes were promising in patients with CR or PR at the time of transplantation, they were dismal in patients with progressive disease. Further advances in chemotherapy, both induction and salvage therapies, are needed to improve the clinical outcomes of patients with LBL.

UR - http://www.scopus.com/inward/record.url?scp=85015586885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015586885&partnerID=8YFLogxK

U2 - 10.3960/jslrt.56.28

DO - 10.3960/jslrt.56.28

M3 - Article

C2 - 27334855

AN - SCOPUS:85015586885

VL - 56

SP - 28

EP - 33

JO - Journal of clinical and experimental hematopathology : JCEH

JF - Journal of clinical and experimental hematopathology : JCEH

SN - 1346-4280

IS - 1

ER -